Zocilurtatug pelitecan - ZAI Lab
Alternative Names: YL-212; ZL-1310Latest Information Update: 16 Nov 2025
At a glance
- Originator ZAI Lab
- Class Antineoplastics; Drug conjugates; Immunoconjugates; Monoclonal antibodies
- Mechanism of Action DNA topoisomerase I inhibitors
-
Orphan Drug Status
Yes - Small cell lung cancer
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase III Small cell lung cancer
- Phase I/II Solid tumours
Most Recent Events
- 11 Nov 2025 Zai Lab plans a phase III trial in Small cell lung cancer (Second line therapy or greater) (Parenteral) (NCT07218146)
- 31 Oct 2025 Phase-III clinical trials in Small cell lung cancer (Second-line therapy or greater, Monotherapy) (IV) (NCT07218146)
- 24 Oct 2025 Efficacy and adverse events data from a phase I trial in Small cell lung cancer released by Zai Lab